Results 11 to 20 of about 34,211 (250)
WikiJournal of Medicine, 2018 Anthracyclines are a clinically important class of antineoplastic agents used to treat a wide variety of solid and blood cancers. The first described anthracycline, daunorubicin, was first isolated from a strain of Streptomyces peucetius in the early ...
Alison Cheong +2 more
doaj +2 more sources
DNA damage independent inhibition of NF-κB transcription by anthracyclines [PDF]
eLife, 2022 Anthracyclines are among the most used and effective anticancer drugs. Their activity has been attributed to DNA double-strand breaks resulting from topoisomerase II poisoning and to eviction of histones from select sites in the genome.
Angelo Ferreira Chora +25 more
doaj +2 more sources
Initial preclinical investigation of aclarubicin treatment in primary cutaneous T-cell lymphoma cells [PDF]
JID InnovationsBetter therapeutic agents are needed in the treatment of advanced cutaneous T-cell lymphomas. Anthracyclines, including doxorubicin, are such drugs, but they are associated with cardiotoxicity that limits treatment.
Fenna J. de Bie +8 more
doaj +2 more sources
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis [PDF]
Experimental Hematology & Oncology, 2012 Background Liposomal formulations of anthracyclines appear to have favorable toxicity profile when compared with conventional anthracyclines in elderly, high risk cardiac patients and patients with prior use of anthracyclines.
Rafiyath Shamudheen M +5 more
doaj +2 more sources
Uptake Assays to Monitor Anthracyclines Entry into Mammalian Cells
Bio-Protocol, 2017 Anthracyclines, such as doxorubicin and daunorubicin, are DNA damaging agents that autofluoresce and can be readily detected in cells. Herein, we developed suitable assays to quantify and localize daunorubicin in mammalian cells.
Nicolas Brosseau +2 more
doaj +2 more sources
Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know [PDF]
Reviews in Cardiovascular Medicine, 2023 Chemotherapies have changed the prognosis of patients affected by cancer over the last 20 years, with a significant increase in survival rates. However, they can cause serious adverse effects that may limit their use.
Armando Ferrera +7 more
doaj +2 more sources
Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
Chinese Medical Journal, 2018 Background: Cardiotoxicity is one of the most serious chronic complications of anthracyclines therapy. Assessment of the left ventricular ejection fraction (LVEF) fails to detect subtle cardiac dysfunction of left ventricular (LV).
Hui-Min Hu +4 more
doaj +2 more sources
Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities. [PDF]
Angew Chem Int Ed EnglA synthetic biology platform was established for the complete refactoring of complex anthracycline biosynthetic pathways in Streptomyces coelicolor using standardized, chemically synthetic DNA parts. This modular construction enabled streamlined combinatorial biosynthesis, yielding novel analogs that decouple DNA damage from chromatin damage (histone ...
Wang R +15 more
europepmc +3 more sources
Predicting Response to Anthracyclines in Ovarian Cancer [PDF]
, 2022 (1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC).
Giuseppe Vizzielli +5 more
core +2 more sources
Molecules, 2021 The aim of this study was to evaluate the bioremoval of anthracycline antibiotics (daunomycin-DNR, doxorubicin–DOX, and mitoxantrone-MTX) by immobilized mycelium of B. adusta CCBAS 930.
Kamila Rybczyńska-Tkaczyk
doaj +1 more source